SCHEMBL3362473

SCHEMBL3362473

CC(C)N1CCCN(c2cncc(-c3cc(C=C4SC(=S)NC4=O)ccc3F)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 1/20 0.42
PIM1 P11309 5/20 0.40
PIM3 Q86V86 2/20 0.40
PIM2 Q9P1W9 2/20 0.40
MYC P01106 3/20 0.39
MAX P61244 3/20 0.39
MTOR P42345 5/20 0.39
NAT1 P18440 1/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RPTOR Q8N122 2/20 0.38
MLST8 Q9BVC4 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE3A Q14432 2/20 0.38
PIK3CD O00329 1/20 0.37
CSNK2A2 P19784 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CG P48736 1/20 0.37
CLK1 P49759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12990361 1.00 PTP4A3 (0.42) PTP4A3PIM1PIM3PIM2MYC
SCHEMBL3362468 1.00 PTP4A3 (0.42) PTP4A3PIM1PIM3PIM2MYC
SCHEMBL12990271 0.93 HIPK2 (0.38) PIM1PIM3PIM2MTORRAB9A
SCHEMBL3362980 0.93 HIPK2 (0.38) PIM1PIM3PIM2MTORRAB9A
SCHEMBL3362984 0.93 HIPK2 (0.38) PIM1PIM3PIM2MTORRAB9A
SCHEMBL3362265 0.90 PIM1 (0.47) PTP4A3PIM1PIM3PIM2MYC
SCHEMBL3363147 0.90 PIM1 (0.47) PTP4A3PIM1PIM3PIM2MYC
SCHEMBL3362258 0.90 PIM1 (0.47) PTP4A3PIM1PIM3PIM2MYC
SCHEMBL3366310 0.82 CYP11B1 (0.39) PIM1PIM3PIM2CSNK2A2CSNK2A1
SCHEMBL3363323 0.82 PIM2 (0.44) PIM1PIM3PIM2MTORPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 PTP4A3 1768/4885PIM1 2/4885PIM3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.